Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells.
暂无分享,去创建一个
J. Becker | L. Pedersen | E. Bröcker | D. Schrama | E. Kämpgen | P. Keikavoussi | M. Andersen | Per thor Straten Pt
[1] J. Becker,et al. Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progression , 2001, International journal of cancer.
[2] J. Becker,et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. , 2001, Cancer research.
[3] Stephen P. Schoenberger,et al. Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation , 2001, Nature Immunology.
[4] D. Speiser,et al. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] J. Becker,et al. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. , 2001, Immunity.
[6] K. Matsushima,et al. Identification of genes specifically expressed in human activated and mature dendritic cells through serial analysis of gene expression. , 2000, Blood.
[7] A. Enk,et al. Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells1 , 2000, The Journal of Immunology.
[8] T. Schumacher,et al. In situ detection of virus- and tumor-specific T-cell immunity , 2000, Nature Medicine.
[9] E. Bröcker,et al. Antigen presentation in extracellular matrix: interactions of T cells with dendritic cells are dynamic, short lived, and sequential. , 2000, Immunity.
[10] A. Haase,et al. Cutting Edge: In Situ Tetramer Staining of Antigen-Specific T Cells in Tissues1 , 2000, The Journal of Immunology.
[11] U. V. von Andrian,et al. The Cc Chemokine Thymus-Derived Chemotactic Agent 4 (Tca-4, Secondary Lymphoid Tissue Chemokine, 6ckine, Exodus-2) Triggers Lymphocyte Function–Associated Antigen 1–Mediated Arrest of Rolling T Lymphocytes in Peripheral Lymph Node High Endothelial Venules , 2000, The Journal of experimental medicine.
[12] A. Enk,et al. Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.
[13] Simon,et al. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection , 1999, Immunology.
[14] W. Oyen,et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. , 1999, Cancer research.
[15] F. Sallusto,et al. Mobilizing Dendritic Cells for Tolerance, Priming, and Chronic Inflammation , 1999, The Journal of experimental medicine.
[16] A. Sette,et al. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. , 1998, Journal of immunology.
[17] S. Rosenberg,et al. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. , 1998, The cancer journal from Scientific American.
[18] P. Guldberg,et al. Detection and Characterization of αβ-T-Cell Clonality by Denaturing Gradient Gel Electrophoresis (DGGE) , 1998 .
[19] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[20] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[21] P. Romero,et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. , 1998, Journal of immunology.
[22] J. Altman,et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.
[23] T. Mcclanahan,et al. A dendritic-cell-derived C–C chemokine that preferentially attracts naive T cells , 1997, Nature.
[24] P. Romero,et al. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. , 1997, Cancer research.
[25] D. Hunt,et al. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. , 1996, Journal of immunology.
[26] P. van Endert,et al. Characterization of antigenic peptides presented by HLA‐B44 molecules on tumor cells expressing the gene MAGE‐3 , 1996, International journal of cancer.
[27] Philip J. R. Goulder,et al. Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.
[28] T. Springer,et al. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. , 1995, Immunology today.
[29] R. Gallo,et al. Tumor antigen presentation by murine epidermal cells. , 1991, Journal of immunology.
[30] A. Halpern,et al. Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.
[31] J. Becker,et al. Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients. , 2001, Cancer research.
[32] C Caux,et al. Immunobiology of dendritic cells. , 2000, Annual review of immunology.
[33] R. Coleman,et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. , 1999, Cancer research.
[34] J. Timmerman,et al. Dendritic cell vaccines for cancer immunotherapy. , 1999, Annual review of medicine.